Repligen Corporation · NASDAQ:RGEN
Repligen — Merger or Acquisition (October 2020)
9 slides from Repligen's merger presentation, Oct 27, 2020
Slide 1: Repligen Announces Agreement to Acquire ARTeSYN Biosolutions
Repligen Announces Agreement to Acquire ARTeSYN Biosolutions Tony J. Hunt, President and CEO October 27th, 2020 Jon K. Snodgres, CFO Exhibit 99.2
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to risks and uncertaintie
Slide 3: Strategic Move to Expand Single-Use Bioprocessing Systems, Components and Flow Paths
Strategic Move to Expand Single-Use Bioprocessing Systems, Components and Flow Paths Gold Standard in Single-Use Systems ARTeSYN Biosolutions is an innovator and a market leader in fully automated cGMP single-use Chromatography, Filtration and Buffer/Media Prep Systems and Flow Paths Complements, Ex
Slide 4: ARTeSYN BioSolutions Meets Repligen's Acquisition Criteria
ARTeSYN BioSolutions Meets Repligen’s Acquisition Criteria Technology leadership in bioprocessing A gold standard in Single-Use Systems design and performance, highly differentiated Strengthens and expands Repligen portfolio Addresses gap in Filtration with TFF Flat Sheet System Expands Systems port
Slide 5: ARTeSYN BioSolutions Company Profile
Headquarters: Waterford, Ireland Founded: 2015 by Michael Gagne Employees: 130 Headquarters: Waterford, Ireland Manufacturing: US (CA), Ireland, Estonia Sales offices: US Distributors: US, EU https://www.artesynbiosolutions.com Products snapshot Single-Use Systems supports 15L-2000L Lab-scale throug
Slide 6: ARTeSYN Biosolutions Revenue Sources
ARTeSYN Biosolutions Revenue Sources BioProcess Systems & Flow Paths ~50% Components and Consumables - ~50% TFF Filtration Systems Chromatography Systems Buffer/Media Prep Systems Over Molded Tubing Sets from EMT Single-Use Flow Paths Valves, Valve Liners, Flow Path Exoskeletons Total Projected Reve
Slide 7: Favorable Financial Impact of ARTeSYN Biosolutions Acquisition
Favorable Financial Impact of ARTeSYN Biosolutions Acquisition Expected to add approximately $33M-$36M of revenue in 2021E Gross margins currently below Repligen corporate average with goal of >50% in 2021 2021 investment focus: commercial integration and commercial pipeline build out Expected to be
Slide 8: Questions? Contact Investor Relations
Questions? Contact Investor Relations investors@repligen.com 781-250-0111
Slide 9: Questions? Contact Investor Relations
Questions? Contact Investor Relations investors@repligen.com 781-250-0111